Q32 BIO INC SEC Filings

QTTB NASDAQ

Welcome to our dedicated page for Q32 BIO SEC filings (Ticker: QTTB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Analyzing a biotech 10-K stuffed with immunology diagrams is challenging enough; doing it for Q32 Bio Inc. (QTTB), with its dual adaptive- and innate-immunity programs, can feel overwhelming. Trial data for bempikibart and ADX-097, cash-runway math, and dilution clauses are buried across multiple SEC documents.

Our platform turns that complexity into clarity. Stock Titan’s AI delivers line-by-line explanations, transforming Q32 Bio annual report 10-K simplified summaries, pinpointing R&D spend, and flagging risk-factor changes. Need the latest Q32 Bio quarterly earnings report 10-Q filing or want Q32 Bio 8-K material events explained? They appear here moments after hitting EDGAR—complete with section-level highlights you can skim in minutes.

Stay ahead of management moves with Q32 Bio insider trading Form 4 transactions. Our feed shows Q32 Bio Form 4 insider transactions real-time, alerting you to option exercises or sales that may precede clinical milestones. You’ll also find:

Q32 Bio proxy statement executive compensation parsed into easy tables
Cash-burn trends and share-issuance details inside every 10-Q
Quick-read notes that make understanding Q32 Bio SEC documents with AI effortless

Whether you’re dissecting a financing 8-K or searching for Q32 Bio executive stock transactions Form 4, our AI-driven dashboard surfaces the facts that matter. Use the built-in comparison tool for Q32 Bio earnings report filing analysis across quarters, monitor trial updates without wading through pages of technical jargon, and make informed decisions faster.

06/25/2025 08:05 AM

Filing

[8-K] Q32 Bio Inc. Reports Material Event

Rhea-AI Summary

Q32 Bio (NASDAQ:QTTB) announced the resignation of Chief Medical Officer Jason Campagna, M.D., Ph.D., effective July 9, 2025. The company has appointed Adrien Sipos, M.D., Ph.D. as Interim Chief Medical Officer, effective the same date. This Form 8-K filing discloses the leadership transition in the company's medical division.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-1.89%

FAQ

What is the current stock price of Q32 BIO (QTTB)?

The current stock price of Q32 BIO (QTTB) is $1.45 as of June 28, 2025.

What is the market cap of Q32 BIO (QTTB)?

The market cap of Q32 BIO (QTTB) is approximately 18.7M.

What is the primary focus of Q32 Bio Inc.?

Q32 Bio Inc. is focused on developing novel biologic therapeutics that restore immune balance by targeting dysregulation in both the adaptive and innate immune systems, particularly in autoimmune and inflammatory diseases.

How does Q32 Bio approach the treatment of autoimmune diseases?

The company uses innovative antibody-based therapeutics, such as bempikibart, to modulate key immune signaling pathways like IL-7 and TSLP, thereby addressing underlying pathological immune responses in autoimmune conditions.

What differentiates Q32 Bio's product candidates?

Q32 Bio differentiates its programs by focusing on both adaptive immunity with bempikibart and innate immunity with ADX-097, the latter of which employs a tissue-targeted approach to complement inhibition that minimizes systemic side effects.

What therapeutic areas are being targeted by Q32 Bio?

The company is exploring treatments for a range of autoimmune and inflammatory conditions, including but not limited to atopic dermatitis, alopecia areata, and complement-mediated disorders affecting various tissue types.

What is the rationale behind targeting IL-7 and TSLP pathways?

By inhibiting the IL-7 and TSLP pathways, Q32 Bio aims to curb T-cell overactivation and the subsequent inflammatory cascade that drives many autoimmune diseases, thereby rebalancing the immune response.

How does Q32 Bio ensure the safety and efficacy of its therapies?

The company conducts comprehensive clinical trials designed to assess safety, pharmacokinetics, and clinical efficacy. This rigorous approach helps build a solid data foundation that meets regulatory standards and informs further development.

How does Q32 Bio stay competitive in the biotherapeutics market?

Q32 Bio leverages its dual focus on both adaptive and innate immunity, advanced antibody engineering, and tissue-targeted complement inhibition to develop differentiated therapies, while adhering to stringent clinical and regulatory standards.

What can investors learn about Q32 Bio's clinical development programs?

Investors can gain insights into the company’s robust clinical trial design, the scientific rationale behind its product candidates, and the transparency of its data-driven approach, all of which underscore its commitment to addressing significant unmet medical needs.

Q32 BIO INC

NASDAQ:QTTB

QTTB Rankings

#5577 Ranked by Market Cap

N/A Ranked by Dividends

QTTB Stock Data

Market Cap 18.66M

Float 9.14M

Insiders Ownership 8.7%

Institutions Ownership 86.37%

Short Percent 8.42%

Industry Biotechnology

Sector Pharmaceutical Preparations

Website Link

Country United States

City WALTHAM